PharmaCom BioVet, Inc. Announces Corporate Vision to Research, Treat and Compassionately Care for Companion Animals Afflicted Wi
07 Ottobre 2008 - 10:00PM
Marketwired
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce
their corporate vision to research, treat and compassionately care
for companion animals afflicted with cancer.
PharmaCom BioVet, Inc. is dedicated to advancing the medical
care industry for companion animals by establishing
state-of-the-art treatment centers for lymphoma and other forms of
cancer throughout the country. The company's focus is on furthering
cancer research, treatment and care for companion animals. Their
primary goals include creating compassionate care facilities to
treat animals afflicted with cancer and to find products in
conjunction with procedures that will eradicate cancer in companion
animals.
"Our ultimate goal is to work towards a day when we can
eradicate cancer in companion animals as we utilize our personal
and professional relationships to create a think tank of the
brightest minds in the veterinary and university fields to advance
research and technology, all while focusing on compassionate care,"
said Gary S. Berthold, Founder and CEO of PharmaCom BioVet.
With 75 million dogs in the United State alone, Americans spend
$9.8 Billion a year on veterinary services. Cancer is the number
one cause of death in dogs, with one out of every three dogs being
diagnosed with cancer and 50% of those dogs will succumb to their
illness.
In response to demand and the current lack of adequate cancer
treatment options and facilities for animal lovers whose pets are
suffering from cancer, PharmaCom BioVet intends to open a network
of companion animal cancer care centers throughout North
America.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the medical
care industry for companion animals by establishing
state-of-the-art treatment centers for lymphoma and other forms of
cancer throughout the country. The purpose of these centers is to
help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also
operate under the philosophy of providing a compassionate care
environment for both companion animal patients and their owners.
For more information, please visit our website
www.PharmaComBioVet.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements that are subject to risk and uncertainties, including,
but not limited to, the impact of competitive products, product
demand, market acceptance risks, fluctuations in operating results,
political risk and other risks detailed from time to time in
PharmaCom BioVet, Inc.'s filings with the Securities and Exchange
Commission. These risks could cause PharmaCom BioVet, Inc.'s actual
results to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, PharmaCom
BioVet, Inc.
Contact: Market Ideas, Inc. 877-295-3981 ext. 2
info@marketideasinc.com
Grafico Azioni PharmaCom BioVet (CE) (USOTC:PHMB)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni PharmaCom BioVet (CE) (USOTC:PHMB)
Storico
Da Mag 2023 a Mag 2024